Both medications embody a emerging class of antibody treatments designed to neutralize the SARS-CoV-2 agent. First, sotrovimab, developed by GSK , demonstrated significant benefit against versions of the https://neilomsy423799.blogdigy.com/sotrovimab-vir-7831-a-deep-exploration-into-the-protein-therapy-67342966